|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||4.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.92|
NEW YORK, NY / ACCESSWIRE / February 8, 2019 / Q BioMed (QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally. The illness often remains undetected long after significant vision loss has already occurred and in the most common form, known as open-angle glaucoma, there are usually no symptoms and no pain associated with the increase in intraocular pressure that leads to optic nerve damage. A 2014 study published in Ophthalmology, the journal of the American Academy of Ophthalmology, by Y.C. Tham et al. of the Singapore Eye Research Institute projected that the number of people worldwide, aged 40 to 80 years, with glaucoma would grow from an estimated 64 million in 2013 to 76 million in 2020 and nearly 112 million people by the year 2040.
NEW YORK, Feb. 7, 2019 /PRNewswire/ -- Q BioMed Inc. (QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company. Expecting several corporate developments and news events, the Company's investor relations consulting firm engaged a new sub-contracted service provider on January 1, 2019, to assist in presenting the Company to a broader audience. The third-party service provider, Platinum Vlll Investment and Media LLC, has several outlets that it contracts with to provide visibility to its clients, including the Company, using its various subscriber bases.
NEW YORK, Feb. 5, 2019 /PRNewswire/ -- www.FinancialBuzz.com, a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with Q Biomed Inc. (QBIO) Chairman and CEO, Denis Corin from the floor of the NASDAQ MarketSite at Times Square New York City. Mr. Corin shares with us his vision of Company's growth and why he believes 2019 and beyond are essential years for Q BioMed Inc. The interview provides unique insight into the Company's latest corporate developments, updates on recently-achieved milestones, and current upcoming catalyst. Additionally, Mr. Corin provides his perspective on how Q BioMed Inc. is well positioned to build upon its current pipelines and creating continued shareholder value.
NEW YORK , Feb. 1, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today the Company's CEO Denis Corin will deliver a corporate presentation and conduct ...
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / Shares of Q BioMed Inc. (QBIO) rose on heavy volume after the company announced that a new collaboration among researchers at McMaster University, Mannin Research and the emerging biotechnology accelerator, focuses on ophthalmic drug delivery and formulation experiments for MAN-01, a first in class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery. With 70 million patients in the world, and with expectations that this will grow to 100 million in the coming years, more effective and more easily delivered glaucoma treatments are needed by ophthalmologists and patients.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.
LOS ANGELES, CA / ACCESSWIRE / January 18, 2019 / A new report indicates that an anticipated key FDA decision is set to transform Q BioMed (QBIO) from a biotech developer to a revenue generating manufacturer in what may be record time. When Corin was asked to acknowledge the "buzz" surrounding upcoming catalysts, he stated: "A lot of the focus over the last year or so has been on the Strontium Chloride Sr-89 Injection or Metastron™ assets because its close to commercialization and I guess the first real commercial catalyst is that we're waiting for FDA approval of the manufacturing facility in South Texas.
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that Pamela Ventola Phd, from Yale University has joined its Advisory Committee for its QBM-001 clinical program. QBM-001 is being developed and tested for the treatment of minimally verbal or non-verbal toddlers with an Autism Spectrum Disorder (ASD).
SmallCapVoice.com, Inc. (SCV) and Q BioMed Inc. (QBIO) (the "Company"), a commercial stage biotechnology company, announced today that a new audio interview with the Company is now available. Denis Corin, CEO of Q BioMed Inc., called in to SmallCapvoice.com to go over the innovative biotechnology firm’s business model, including a discussion about a key pending FDA catalyst which is set to help transform the company into a revenue generating biotech. Corin also dissects the importance of Q BioMed’s acquisition of Cancer Pain Drug Metastron™ from GE Healthcare and goes over the markets they aim to serve with their innovative products and formulations in various other indications.
Q BioMed Inc. (QBIO), a commercial stage biotechnology company provides the following update to its shareholders and interested investors. It's been proven safe and effective over many years of use.
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children. SRI has broad expertise in solving formulation, drug delivery, and characterization challenges of small molecule drugs and biologics.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare. The agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to Q BioMed to allow for as seamless a transition as possible in all markets.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to announce that Robert Derham, a member of the Q BioMed team and founder of CheckOrphan and architect of the world's first access program database, hosted a roundtable discussion on how companies can compliantly communicate their expanded access program and participated on a panel discussion about how to more effectively work with patients and patient organizations when executing an expanded access program. Expanded access programs are highly regulated programs that provide people with medicine that has not yet been approved on the market.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to provide an update on QBM001, its Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children. Q BioMed continues to develop its intellectual property including its patent pending QBM-001 drug technology, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.
Q BioMed Inc. (QBIO), is pleased to announce that it has entered into a definitive agreement with Yorkville Advisors Global ('Yorkville') for $4,000,000. Q BioMed has closed on the initial tranche of $2,000,000 and expects to close on the balance pending the filing of a registration statement with the U.S. Securities and Exchange Commission for the underlying shares. Q BioMed Inc. CEO, Denis Corin said, "We are very pleased to once again partner with Yorkville as we enter a very milestone intensive period for Q BioMed.
Distinguished Ophthalmology Specialist Brings Wealth of Experience NEW YORK , Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, ...
NEW YORK, Aug. 20, 2018 /PRNewswire/ -- Q BioMed Inc. (QBIO) (QBIO), a commercial stage biotechnology acceleration development company, and BioNucleonics, licensor of Strontium 89 Chloride, announce submission of a supplemental regulatory filing to the FDA for the approval of a new manufacturing facility. Once cleared by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP in accordance with cGMP. Strontium Chloride Sr89 Injection USP is an FDA-approved non-opioid injectable radiopharmaceutical indicated to relieve cancer bone pain in patients with painful skeletal metastases.
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and usability of GDF15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma. The extension allows for more extensive evaluation to be conducted on the feasibility and usability of GDF15 as a novel biomarker for glaucoma and companion diagnostic to, Q BioMed's exclusively licensed technology, MAN-01.
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform technology asset from Mannin Research Inc. Together with Mannin Research, the company has made significant progress on their Tie2 activating molecule - currently being optimized for a topical eye drop for the treatment of open angle glaucoma. This is a tremendous achievement and involved significant and detailed work, giving them broad coverage of the platform from an intellectual property standpoint.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, placed second in the 'company category' at this year's Bay Area Autism Speaks Walk. The fundraiser provided Q BioMed an opportunity to connect with and better understand the autism spectrum disorder (ASD) community as the company progresses with QBM-001, which is being developed to treat pediatric developmental nonverbal disorder in toddlers with ASDs. "We gave it an all-out team effort to support the autism community, and we are happy to support Autism Speaks' efforts to raise awareness and educate, fund research, and support patients and caregivers," explained Denis Corin, CEO of Q BioMed.
NEW YORK , April 5, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer, will present at ...
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the FDA for the approval of a new manufacturing facility. Upon approval by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP (Strontium-89) in accordance with cGMP. Strontium-89 is a non-opioid injectable radiopharmaceutical to relieve cancer bone pain in patients with painful skeletal metastases.
NEW YORK , March 9, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer will present at the ...
OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for ...
NEW YORK, NY / ACCESSWIRE / February 2 2 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of CytoDyn Inc. (OTCQB: CYDY ) and Q Biomed Inc. (OTCQB: QBIO ...